How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

NANot yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2026

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2028

Conditions
Metabolic Dysfunction-Associated Steatotic Liver DiseaseNon-Alcoholic Steato-Hepatitis (NASH)Type 1 Diabetes Mellitus
Interventions
DIAGNOSTIC_TEST

Imaging PET/MRI

"MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed.~\[11C\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \[18F\]-FTHA: oral administration of 75 MBq followed by TEP imaging."

DIAGNOSTIC_TEST

Stable isotope infusions

"\[6,6 D2\]-glucose infusion (0.22 µmol/kg/min, preceded by a bolus of 22 µmol/kg) will start from -180 until time + 360.~\[1,1,2,3,3-2H\]-glycerol (0.05 µmol/kg/min.) and of \[7,7,8,8-2H\] palmitate (0.01 µmol/kg/min) will start from time -60 until time +360."

DIAGNOSTIC_TEST

meal test

A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\[13C\]-glucose and 9 μmol/kg lean mass of \[U-13C\]-palmitate.

DIAGNOSTIC_TEST

Indirect calorimetry

Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.

Trial Locations (1)

J1H 5N4

Centre de recherche du CHUS, Sherbrooke

All Listed Sponsors
collaborator

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

OTHER

lead

Université de Sherbrooke

OTHER